Meta-analysis of 20 RCTs (83,288 participants with type 2 diabetes or cardiometabolic disease): GLP-1 receptor agonists were not associated with a higher risk of optic nerve or vision-threatening events (OR 1.20, 95% CI 0.73-1.97).
Meta-analysisn = 83,288
Li et al. GLP-1 Receptor Agonists and Risk of Optic Nerve or Vision-Threatening Events in Patients With Type 2 Diabetes or Cardiometabolic Diseases: A Meta-analysis of Randomized Controlled Trials